Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary.
Cavazzoni A, Salamon I, Fumarola C, Gallerani G, Laprovitera N, Gelsomino F, Riefolo M, Rihawi K, Porcellini E, Rossi T, Mazzeschi M, Naddeo M, Serravalle S, Broseghini E, Agostinis F, Deas O, Roncarati R, Durante G, Pace I, Lauriola M, Garajova I, Calin GA, Bonafè M, D'Errico A, Petronini PG, Cairo S, Ardizzoni A, Sales G, Ferracin M.
Cavazzoni A, et al. Among authors: d errico a.
Mol Ther. 2024 Jul 20:S1525-0016(24)00466-0. doi: 10.1016/j.ymthe.2024.07.011. Online ahead of print.
Mol Ther. 2024.
PMID: 39033323